InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026)
InfuSystem Holdings (INFU) posted Cash from Financing Activities of -$790000.0 for Q1 2026, up 70.77% on a QoQ basis from -$2.7 million in Q4 2025, and down 142.47% year-over-year from $1.9 million in Q1 2025.
InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026) Analysis & Trends
InfuSystem Holdings' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$790000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 142.47% year-over-year to -$790000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 209.15% YoY) and the FY2025 annual result came in at -$15.0 million, down 116.05% from the prior year.
- Cash from Financing Activities was -$790000.0 for Q1 2026 at InfuSystem Holdings, up from -$2.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $3.7 million in Q2 2024 and bottomed at -$8.0 million in Q3 2025.
- A 5-year average of -$2.0 million and a median of -$1.7 million in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 4117.35% — and 2024, when it surged 1679.15%.
- InfuSystem Holdings' Cash from Financing Activities stood at -$1.7 million in 2022, then sank by 107.01% to -$3.5 million in 2023, then declined by 27.4% to -$4.5 million in 2024, then surged by 40.13% to -$2.7 million in 2025, then surged by 70.77% to -$790000.0 in 2026.
- Business Quant data shows INFU's Cash from Financing Activities at -$790000.0 in Q1 2026, -$2.7 million in Q4 2025, and -$8.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | InfuSystem Holdings | 179.47 Mn | 177.37 Mn | 19.68 Mn | -790,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790,000.00 |
| Mar 31, 2026 | -790,000.00 |
| Dec 31, 2025 | -2.70 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 632,000.00 |
| Mar 31, 2024 | 632,000.00 |
| Dec 31, 2023 | -3.54 Mn |
| Dec 31, 2023 | -3.54 Mn |